Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study

Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, TNBCs are often treated with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current problems in cancer. Case reports 2025-03, Vol.17, p.100334, Article 100334
Hauptverfasser: Dietrich, Martin, Velez, Michel
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, TNBCs are often treated with surgery, chemotherapy, radiation, and, most recently, with immunotherapy; however, patients with treatment-resistant TNBC often relapse and have an extremely poor prognosis. Here we present a case of recurrent metastatic TNBC responsive to the TRK inhibitor larotrectinib.
ISSN:2666-6219
2666-6219
DOI:10.1016/j.cpccr.2024.100334